67 Table 6: Volume of blood to be drawn from each patient in the study .............................. 80 TABLE OF FIGURES Figure 1: Study Design – Immune response assessment ................................................................ 33 Figure 2: Study Design – Dose Limiting Toxicity Assessment ..................................................... 34 Figure 3: Treatm ent schedule for patients starting vaccination and receiving chemotherapy later – Main group ........................................................................................................... 34 Figure 4: Treatment schedule for patients starting vacc ination and chemotherapy at the same time – concomitant group ............................................................................................. 36 Figure 5: Treatment schedule for patients starting vaccination and receiving chemotherapy later – Modified vaccination group ................................................................................. 36 Figure 6: DTH Skin Reaction Registration (induration and erythaema) ....................................... 66 TABLE OF APPENDICES APPENDIX I: FURTHER GUIDANCE ON THE DEFINITION OF A SERIOUS ADVERSE EVENT (SAE) ......................................................................................................